Shares of Hologic (NASDAQ:HOLX) have been assigned an average recommendation of “Buy” from the fifteen ratings firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have given a hold recommendation and nine have given a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $47.54.
Several equities analysts have recently commented on HOLX shares. Canaccord Genuity reaffirmed a “buy” rating and set a $48.00 price objective on shares of Hologic in a research note on Friday, February 9th. Needham & Company LLC reissued a “buy” rating and issued a $50.00 price target on shares of Hologic in a research note on Friday, February 9th. Cowen raised shares of Hologic to a “buy” rating and set a $52.00 price target for the company in a research note on Wednesday, December 20th. Bank of America raised shares of Hologic from a “neutral” rating to a “buy” rating and set a $50.00 price target for the company in a research note on Thursday, January 4th. Finally, Zacks Investment Research raised shares of Hologic from a “hold” rating to a “buy” rating and set a $43.00 price target for the company in a research note on Tuesday, February 13th.
In other Hologic news, Director Charles J. Dockendorff bought 13,000 shares of the firm’s stock in a transaction on Thursday, March 15th. The stock was acquired at an average price of $38.80 per share, with a total value of $504,400.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Allison P. Bebo sold 7,000 shares of the firm’s stock in a transaction that occurred on Friday, March 16th. The shares were sold at an average price of $38.75, for a total transaction of $271,250.00. The disclosure for this sale can be found here. 0.79% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Chevy Chase Trust Holdings Inc. increased its stake in shares of Hologic by 1.4% during the third quarter. Chevy Chase Trust Holdings Inc. now owns 244,620 shares of the medical equipment provider’s stock valued at $8,975,000 after purchasing an additional 3,391 shares in the last quarter. Janus Henderson Group PLC increased its stake in shares of Hologic by 15.5% during the third quarter. Janus Henderson Group PLC now owns 285,035 shares of the medical equipment provider’s stock valued at $10,458,000 after purchasing an additional 38,283 shares in the last quarter. Fiduciary Trust Co. bought a new position in shares of Hologic during the fourth quarter valued at approximately $208,000. Ladenburg Thalmann Financial Services Inc. increased its stake in shares of Hologic by 66.4% during the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,487 shares of the medical equipment provider’s stock valued at $458,000 after purchasing an additional 4,984 shares in the last quarter. Finally, Endurant Capital Management LP increased its stake in shares of Hologic by 115.9% during the fourth quarter. Endurant Capital Management LP now owns 222,844 shares of the medical equipment provider’s stock valued at $9,527,000 after purchasing an additional 119,641 shares in the last quarter. 97.56% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ:HOLX traded down $1.02 during midday trading on Friday, hitting $36.43. 2,194,296 shares of the stock traded hands, compared to its average volume of 2,562,864. The company has a market cap of $10,073.95, a price-to-earnings ratio of 17.95, a price-to-earnings-growth ratio of 1.64 and a beta of 0.85. The company has a current ratio of 1.25, a quick ratio of 0.98 and a debt-to-equity ratio of 0.87. Hologic has a one year low of $35.33 and a one year high of $46.80.
Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Thursday, February 8th. The medical equipment provider reported $0.55 EPS for the quarter, beating the consensus estimate of $0.50 by $0.05. The firm had revenue of $791.10 million during the quarter, compared to the consensus estimate of $785.80 million. Hologic had a net margin of 34.53% and a return on equity of 20.07%. The company’s quarterly revenue was up 7.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.52 earnings per share. research analysts forecast that Hologic will post 2.25 EPS for the current fiscal year.
WARNING: “Hologic (HOLX) Given Average Rating of “Buy” by Analysts” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/08/hologic-holx-given-average-rating-of-buy-by-analysts.html.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.